SEC Filing Summary: Coeptis Therapeutics Holdings, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Coeptis Therapeutics Holdings, Inc. (not Z Squared Inc.) on January 21, 2025. The registrant is a Delaware corporation with principal executive offices in Wexford, Pennsylvania. The filing addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
- Regulatory Compliance: The Company previously received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock closing bid price remaining below $1.00 per share for 30 consecutive business days.
- Resolution: On January 21, 2025, Nasdaq notified the Company that it has regained compliance with the $1.00 minimum bid price requirement.
- Status: The matter regarding the listing deficiency is now closed.
Outlook, Risks, and Management Commentary
Management confirmed the restoration of compliance via a press release issued on January 22, 2025. The filing indicates no new risks or contingencies beyond the resolution of the prior listing deficiency. The Company continues to list its Common Stock (COEP) and Warrants (COEPW) on the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current trading price of COEP to ensure it remains above the $1.00 threshold to maintain compliance.
- Review the press release dated January 22, 2025 (Exhibit 99.1) for additional context on the stock price recovery.
- Confirm the continued listing status of both Common Stock and Warrants on the Nasdaq Capital Market.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.